News Search Results
Dec 10, 2025, 08:00 ET Expression Therapeutics Appoints Industry Veteran Dr. David Townson as Chief Executive Officer
access.About Expression Therapeutics Expression Therapeutics, Inc., based in Atlanta, Georgia, is a clinical-stage biotechnology company pioneering a curative gene therapy for hemophilia A and best-in-class cell therapies for neuroendocrine tumors (NETs) and neuroblastoma.
More news about: Expression Therapeutics, Inc.
Dec 10, 2025, 07:45 ET Publication in Nature's Scientific Reports Reinforces Spiderwort Biotechnologies' Cellulose-Based Platform with New Findings on Neural Repair and Motor Recovery
interdisciplinary academic research combining basic and applied research can accelerate discovery and translate scientific research into meaningful biotechnology innovations and commercial applications.""Spinal cord injury remains one of the most challenging conditions in neurosurgery and
More news about: Spiderwort Biotechnologies Inc.
Dec 10, 2025, 04:15 ET Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
(Nasdaq: SGMT) for exclusive rights in Greater China.About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Dec 09, 2025, 20:30 ET D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing
More news about: D3 Bio, Inc.
Dec 09, 2025, 16:07 ET BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair
Mr. Pagano is currently Chief Financial Officer and Executive Vice President of Genmab, a leading international biotechnology company, a position he has held since March 2020. He joined Genmab in December 2007, establishing a strong track record of driving financial performance
More news about: BillionToOne
Dec 09, 2025, 16:01 ET AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Dec 09, 2025, 15:30 ET Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Greenbrier South, Huntsville, Alabama site was selected from more than 300 applications, partly based on its proximity to the HudsonAlpha Institute for Biotechnology, an established bioscience campus that supports workforce training and research. In addition to its workforce potential, the region offers ready
More news about: Eli Lilly and Company
Dec 09, 2025, 10:20 ET Immunostimulant Market to Reach $288.82 billion, Globally, by 2034 at 9.9% CAGR: Allied Market Research
infectious diseases, increasing prevalence of cancer and immune-related disorders, expanding vaccination initiatives, and continuous advancements in biotechnology, the immunostimulant market is gaining strong traction globally across prophylactic and therapeutic segments.Request Sample of the Report
More news about: Allied Market Research
Dec 09, 2025, 10:15 ET High-end Refractometer Market worth $0.38 billion by 2032 - Exclusive Report by MarketsandMarkets™
the high-end refractometer market include increasing demand for precise, real-time concentration and purity measurement across pharmaceuticals, biotechnology, food and beverage processing, and semiconductor manufacturing. The adoption of advanced optical technologies-such as multi-wavelength measurement,
More news about: MarketsandMarkets
Dec 09, 2025, 08:38 ET Sen-Jam Pharmaceutical Appoints Global Life Sciences Leader Rute Fernandes as Executive Advisor to Accelerate Commercialization Pathways
Sen-Jam Pharmaceutical is a clinical-stage biotechnology company reimagining how inflammation and addiction are treated through innovative, affordable, and rapidly deployable combination therapeutics.
More news about: Sen-Jam Pharmaceutical
Dec 09, 2025, 08:30 ET Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
Dec. 9, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced a newly published study from the Mayo
More news about: Avant Technologies Inc.
Dec 09, 2025, 08:28 ET Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Dec 09, 2025, 08:00 ET Vincere Cancer Center Begins Recruitment for Clinical Studies of Pioneering Breast Cancer Screen for Women at High Risk
detectionCALGARY, AB, Dec. 9, 2025 /PRNewswire/ - Syantra, Inc., a biotechnology company revolutionizing cancer detection, is announcing Scottsdale, Arizona based Vincere Cancer Center has launched recruitment for clinical testing
More news about: Syantra Inc.
Dec 09, 2025, 08:00 ET Curis Provides Updated Data from its Frontline AML Triplet Study
LEXINGTON, Mass., Dec. 9, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated
More news about: Curis, Inc.
Dec 09, 2025, 08:00 ET CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy
CAMBRIDGE, Mass., Dec. 9, 2025 /PRNewswire/ -- CREATE Medicines Inc., a clinical-stage biotechnology company pioneering in vivo multi-immune programming, today announced that the first patient has been dosed in the frontline cohort of its metastatic
More news about: CREATE Medicines, Inc.
Dec 09, 2025, 08:00 ET Miami Biotech Collective Hosts Inaugural 2025 Annual Summit: The Art of Driving the Future of Biotech in South Florida
visibility to Miami's emerging biotech activity. Together, alongside local and national partners, we are positioning South Florida as a leading hub for biotechnology.Learn more at
More news about: Miami Biotech Collective
Dec 09, 2025, 08:00 ET Sameh Samir Ali's Research Fund project is approved by National Natural Science Foundation of China (NSFC)
rankings—serves as Ali's academic home and the foundation of his international scientific career.Within this setting, Ali's research links microbial biotechnology with the broader goal of building low-carbon, data-driven agricultural solutions. By transforming industrial pollutants into biofuels and reusable
More news about: Jiangsu University
Dec 09, 2025, 07:45 ET Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market
SACRAMENTO, Calif., Dec. 9, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three clinically relevant Parkinson's disease subtypes and prioritized
More news about: Lunai Bioworks Inc.
Dec 09, 2025, 07:30 ET Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Dec 09, 2025, 00:00 ET Miltenyi Biotec Receives 'Special Recognition Award' for Pioneering Work in Cell & Gene Therapy at BioSpectrum India Excellence Awards 2025
with this vision, Miltenyi Biotec India recently partnered with BRIC-Translational Health Science and Technology Institute (BRIC-THSTI) and the Biotechnology Industry Research Assistance Council (BIRAC) to introduce India's first practical 'Foundations of Cell and Gene Therapy' program. The initiative
More news about: Miltenyi Biotec
Dec 08, 2025, 16:05 ET Jim Lang Elected to Halozyme's Board of Directors
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Dec 08, 2025, 14:45 ET Hemab Therapeutics Announces Positive Complete Phase 2 Data for Sutacimig in Glanzmann Thrombasthenia at ASH 2025; Plans to Advance to Pivotal Phase 3 Study
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Dec. 8, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced positive results
More news about: Hemab Therapeutics
Dec 08, 2025, 14:05 ET Lilly declares first-quarter 2026 dividend
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Dec 08, 2025, 13:05 ET Florida Health Sciences Center | Tampa General Hospital's John Couris Is Named One of Health Care's Most Influential Figures by Modern Healthcare
Tampa Medical & Research District — an international destination for clinical care, research and biotechnology in collaboration with USF Health. His advocacy at the state and federal levels has helped shape health policy, including the At HOME Services Act
More news about: Tampa General Hospital
Dec 08, 2025, 10:45 ET Precision Fermentation Market is expected to generate a revenue of USD 34.2 Billion by 2032, Globally, at 40.1% CAGR: Verified Market Research®
support from venture capital firms, corporate funds, and government programs enables rapid growth of precision fermentation startups and established biotechnology companies.Large-scale funding supports R&D, pilot programs, and regulatory validation.Investors focus on alternative
More news about: Verified Market Research